Nanjing Leads Biolabs Co., Ltd. (HKG:9887)

Nanjing Leads Biolabs Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023
Revenue	-	-	8.87
Cost of Revenue	-	-	3.19
Gross Profit	-	-	5.68
Selling, General & Admin	64.76	87.69	38.05
Research & Development	233.5	185.68	230.86
Operating Expenses	298.25	273.38	268.91
Operating Income	-298.25	-273.38	-263.23
Interest Expense	-7	-5.76	-1.4
Interest & Investment Income	9.31	8.29	6.55
Currency Exchange Gain (Loss)	1.13	2.04	2.77
Other Non Operating Income (Expenses)	6.42	7.96	3.96
EBT Excluding Unusual Items	-288.39	-260.85	-251.35
Gain (Loss) on Sale of Investments	1.18	1.72	6.44
Other Unusual Items	-	-42.08	-117.33
Pretax Income	-287.21	-301.22	-362.25
Net Income	-287.21	-301.22	-362.25
Net Income to Common	-287.21	-301.22	-362.25
Shares Outstanding (Basic)	155	150	145
Shares Outstanding (Diluted)	155	150	145
Shares Change (YoY)	-	3.56%	-
EPS (Basic)	-1.86	-2.01	-2.50
EPS (Diluted)	-1.86	-2.01	-2.50
Free Cash Flow	-	-121.79	-204.41
Free Cash Flow Per Share	-	-0.81	-1.41
Gross Margin	-	-	64.07%
Operating Margin	-	-	-2969.26%
Profit Margin	-	-	-4086.28%
Free Cash Flow Margin	-	-	-2305.84%
EBITDA	-280.19	-253.13	-243.49
D&A For EBITDA	18.07	20.24	19.74
EBIT	-298.25	-273.38	-263.23

Source: S&P Global Market Intelligence. Standard template. Financial Sources.